Gilead Sciences antibody drug conjugate Trodelvy is now approved as a first-line treatment for triple-negative breast cancer. This expanded approval for Trodelvy comes with a slightly broader label that gives it an edge over the AstraZeneca and Daiichi Sankyo ADC Datroway.
The post New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer appeared first on MedCity News.
